October was Breast Cancer Awareness Month. According to the CDC, one in eight women will contract breast cancer. It is the ...

Researchers have found an association between baseline circulating tumor cell count and survival in metastatic ...

Metastatic castration-resistant prostate cancer (mCRPC) is a severe form of late-stage disease where the tumor can no longer ...

Neal Shore, MD, FACS, discussed a study on survival outcomes in metastatic castration-sensitive prostate cancer comparing ...

According to the 2019 National Cancer Registry the lifetime risk for prostate cancer in South Africa is 1 in every 15 man. Prostate cancer is the most common cancer in men globally and is showing a ...

During Movember, Michaela Hagenhofer, general manager, commercial operations at Johnson & Johnson Innovative Medicine, ...

The treatment landscape for patients with prostate cancer, especially individuals with advanced disease, has dramatically changed in recent years. However, aside from drug or hormonal therapies, other ...

Androgen deprivation is the mainstay of advanced prostate cancer treatment. Despite initial responses, almost all patients progress to castration-resistant prostate cancer (CRPC). The ...

Medically reviewed by Amelia MacIntyre, DO Approximately 1 in 8 people with a prostate are diagnosed with prostate cancer ...

We remain on track for phase 2b and phase 3 topline data in non-metastatic, localized prostate cancer for CAN-2409 in the fourth quarter ...

Panbela Therapeutics Inc (PBLA) secures a $12 million loan to bolster clinical trials, but faces liquidity concerns and ...

A research team led by UCLA Health Jonsson Comprehensive Cancer Center investigators has shown that combining pembrolizumab, ...